PubRank

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Clinical Trial ID NCT01479244

PubWeight™ 18.64‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01479244

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014 1.88
2 Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2011 1.38
3 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
4 Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology 2015 1.13
5 The immune system and inflammation in breast cancer. Mol Cell Endocrinol 2013 1.12
6 Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013 0.99
7 Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother 2008 0.86
8 Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology 2014 0.85
9 Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) 2014 0.82
10 Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014 0.82
11 Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother 2014 0.81
12 A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J 2014 0.81
13 Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 2015 0.80
14 Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy. Hum Vaccin Immunother 2014 0.78
15 Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc 2015 0.78
16 Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe Frauenheilkd 2015 0.78
17 A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci 2016 0.78
18 Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol 2015 0.77
19 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
20 The Promise of Preventive Cancer Vaccines. Vaccines (Basel) 2015 0.77
21 Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol 2016 0.77
22 Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel) 2016 0.75
23 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014 0.75
Next 100